Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis

NCT00099255 is registered in ClinicalTrials.gov with Seagen Inc. as lead sponsor.

NCT NCT00099255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00099255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multi-Dose Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma, Large Cell Transformation of Mycosis Fungoides, and Lymphomatoid Papulosis
Lead sponsor
Seagen Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2004
Completion date
February 28, 2007
Enrollment
40
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

large cell lymphoma